Karen N McFarland
Overview
Explore the profile of Karen N McFarland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
721
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koller E, McFarland K, Angelle C, Howard J, Ryu D, Dillon K, et al.
Acta Neuropathol Commun
. 2025 Mar;
13(1):51.
PMID: 40055831
Multiple lines of evidence indicate that immune signaling can impact the pathological progression in Alzheimer's disease (AD), including amyloid deposition, tau aggregation, synaptic pathology and neurodegenerative trajectory. In earlier studies,...
2.
Simon Z, McFarland K, Golde T, Chakrabarty P, Febo M
bioRxiv
. 2024 Aug;
PMID: 39131384
Extracellular beta-amyloid (Aβ) is thought to cause impairments in brain-wide functional connectivity, although mechanisms linking Aβ to broader functional network processing remain elusive. In the present study, we evaluated the...
3.
Asken B, DeSimone J, Wang W, McFarland K, Arias F, Levy S, et al.
Alzheimers Dement (Amst)
. 2024 Jul;
16(3):e12617.
PMID: 39021585
Introduction: Commercially available plasma p-tau217 biomarker tests are not well studied in ethnically diverse samples. Methods: We evaluated associations between ALZPath plasma p-tau217 and amyloid-beta positron emission tomography (Aβ-PET) in...
4.
McFarland K, Tiwari A, Hashem V, Zhang L, Zeng D, Vincent J, et al.
Hum Mol Genet
. 2024 Jun;
33(18):1567-1574.
PMID: 38832639
Spinocerebellar ataxia type 10 (SCA10) is a rare autosomal dominant ataxia caused by a large expansion of the (ATTCT)n repeat in ATXN10. SCA10 was described in Native American and Asian...
5.
Weber D, Taylor S, Lagier R, Kim J, Goldman S, Clarke N, et al.
Front Neurol
. 2024 Apr;
15:1364658.
PMID: 38595851
Introduction: Plasma Aβ42/40 ratio can help predict amyloid PET status, but its clinical utility in Alzheimer's disease (AD) assessment is unclear. Methods: Aβ42/40 ratio was measured by LC-MS/MS for 250...
6.
DeSimone J, Wang W, Loewenstein D, Duara R, Smith G, McFarland K, et al.
Alzheimers Dement
. 2024 Mar;
20(4):2830-2842.
PMID: 38441274
Introduction: Magnetic resonance imaging (MRI) biomarkers are needed for indexing early biological stages of Alzheimer's disease (AD), such as plasma amyloid-β (Aβ42/40) positivity in Aβ positron emission tomography (PET) negative...
7.
Weber D, Taylor S, Lagier R, Kim J, Goldman S, Clarke N, et al.
medRxiv
. 2024 Jan;
PMID: 38168329
Introduction: Plasma Aβ42/40 ratio can be used to help predict amyloid PET status, but its clinical utility in Alzheimer's disease (AD) assessment is unclear. Methods: Aβ42/40 ratio was measured by...
8.
Moore B, Ran Y, Goodwin M, Komatineni K, McFarland K, Dillon K, et al.
Mol Ther Methods Clin Dev
. 2023 Nov;
31:101146.
PMID: 38027063
Enhancing production of protein cargoes delivered by gene therapies can improve efficacy by reducing the amount of vector or simply increasing transgene expression levels. We explored the utility of a...
9.
Cid R, Ortega A, Crocco E, Hincapie D, McFarland K, Duara R, et al.
Front Neurol
. 2023 Aug;
14:1179205.
PMID: 37602238
Introduction: Semantic intrusion errors (SI) have distinguished between those with amnestic Mild Cognitive Impairment (aMCI) who are amyloid positive (A+) versus negative (A-) on positron emission tomography (PET). Method: This...
10.
De La Cruz E, Vo Q, Moon K, McFarland K, Weinrich M, Williams T, et al.
Int J Mol Sci
. 2022 Jul;
23(15).
PMID: 35897751
MHCII molecules, expressed by professional antigen-presenting cells (APCs) such as T cells and B cells, are hypothesized to play a key role in the response of cellular immunity to α-synuclein...